CyclopharmASX:CYC 46 Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus rates ASX:CYC with a GF Score™ of 46/100 and a GF Value™ of A$0.84 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 68 Medical Distribution companies, Cyclopharm ranks worse than 1470586.76% on this metric.
As of today (2026-06-28), the Forward Annual Dividend Yield of Cyclopharm is 0.00%.
As of today (2026-06-28), the Trailing Annual Dividend Yield of Cyclopharm is 0.00%.
ASX:CYC's Forward Dividend Yield % is not ranked *
in the Medical Distribution industry.
Industry Median: 2.96 * Ranked among companies with meaningful Forward Dividend Yield % only.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Cyclopharm was 26.00% per year. The lowest was 0.00% per year. And the median was 0.00% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
ASX:CYC vs MCK, COR, CAH: Forward Dividend Yield % Comparison
For the Medical Distribution subindustry, Cyclopharm's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclopharm Forward Dividend Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cyclopharm's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Cyclopharm's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Cyclopharm (ASX:CYC) has a Forward Dividend Yield % of 0.00% as of Jun. 28, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Cyclopharm and its competitors. According to the industry distribution chart, Cyclopharm ranks #999999 out of 68 companies in the Medical Distribution industry.
Is Cyclopharm's Forward Dividend Yield % too high?
Cyclopharm's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Cyclopharm ranks #999999 out of 68 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cyclopharm has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's Forward Dividend Yield % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Cyclopharm ranks #999999 out of 68 companies for Forward Dividend Yield %. This places Cyclopharm in the lower half of its industry. The industry median Forward Dividend Yield % is 2.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Distribution company?
The median Forward Dividend Yield % among Medical Distribution companies is 2.96, based on 68 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Cyclopharm and its competitors. For the Medical Distribution industry, the median Forward Dividend Yield % is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclopharm's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.50 — trading 40.5% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Cyclopharm's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyclopharm (ASX:CYC) Overvalued in 2026?
Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued.
The current stock price of A$0.50 is trading 40.5% below its estimated GF Value™ of A$0.84.
GuruFocus considers Cyclopharm to be Possible Value Trap.
Key valuation signals for ASX:CYC:
Forward Dividend Yield %: 0.00%
GF Value™: A$0.84 vs. price of A$0.50 (40.5% below fair value)
No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
46GF Score
Get the complete analysis for ASX:CYC
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYC has been successfully added to your 